Liver Cirrhosis Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder

Reviewed by ExomeDNA Editorial Process · [/methodology/editorial-process]

Last reviewed: 2026-05-29

Disclaimer: This content is educational and informational. For health decisions, consult a clinician.

Liver Cirrhosis Risk is a genetically influenced health trait reflecting how common variants in genes such as PNPLA3, SERPINA1, and HSD17B13 may relate to population-level patterns of liver scarring. Cirrhosis represents late-stage liver damage in which healthy tissue is progressively replaced by scar tissue, impairing organ function over time. Research suggests that specific inherited variants can affect how the liver handles fat, oxidative stress, and protein folding — processes involved in cirrhosis progression. This page covers the biology behind that risk, what the research says, and how people use this kind of information alongside lifestyle and clinical context.

What is liver cirrhosis?

Liver cirrhosis is a condition in which the liver's internal architecture is disrupted by the accumulation of fibrous scar tissue, typically developing after sustained or repeated injury. Common causes include chronic alcohol use, non-alcoholic fatty liver disease (NAFLD), and viral hepatitis infections. As fibrosis advances, fewer functional liver cells remain, reducing the organ's capacity for detoxification, protein synthesis, and metabolic regulation. Population studies have consistently shown that genetic background interacts with lifestyle and environmental exposures to influence who develops cirrhosis and at what pace.

The genetics behind liver cirrhosis

Several genes appear consistently in genome-wide association studies examining cirrhosis risk and related liver traits. The evidence for each varies, and the signals discussed here reflect population-level associations rather than deterministic predictions for any individual.

SERPINA1 encodes alpha-1-antitrypsin, a protein that protects the liver — and lungs — from enzyme-mediated damage. Certain inherited SERPINA1 variants cause misfolded protein to accumulate inside liver cells rather than being secreted normally. This cellular stress has been associated with progressive liver injury. The SERPINA1 signal in this trait shows the highest statistical confidence among the genes examined here.

MTARC1 (also referred to as MARC1 in some literature) encodes a mitochondria-associated enzyme involved in nitrogen metabolism and lipid handling. Research suggests that variation near MTARC1 is associated with liver fat content and fibrosis outcomes, though the precise mechanism remains an active area of investigation.

PNPLA3 encodes patatin-like phospholipase domain-containing protein 3, expressed in liver and fat cells. Variants in PNPLA3 have been among the most replicated genetic findings in non-alcoholic fatty liver disease and cirrhosis research. The protein appears to influence how the liver processes and stores lipids; specific variants have been associated with increased hepatic fat accumulation.

HSD17B13 encodes a liver-expressed hydroxysteroid dehydrogenase involved in lipid metabolism. Loss-of-function variants in HSD17B13 have been studied in relation to liver disease progression; research suggests that certain variants may modulate the trajectory of liver injury, potentially buffering against more severe outcomes in the context of other risk factors.

TM6SF2 encodes transmembrane 6 superfamily member 2, a protein expressed in liver and intestine that influences lipid secretion. Studies have associated TM6SF2 variation with hepatic triglyceride content and liver disease severity.

Additional signals near KLHL8 and MARC1 appear in this dataset with lower confidence scores, and their roles in liver biology are less established.

KEY STAT A multi-trait genome-wide association study identified shared genetic architecture between cirrhosis and several related metabolic and liver traits, with SERPINA1, PNPLA3, and TM6SF2 among the most prominent loci (Emdin 2021^[1]).

What the research says

Research base: Moderate.

The scientific basis for genetic associations with liver cirrhosis has advanced considerably over the past decade, though much of the causal pathway remains under active investigation. The primary study informing this trait is a multi-trait genome-wide association and gene-environment interaction analysis, which examined cirrhosis-related signals across overlapping metabolic phenotypes (Emdin 2021^[1]).

The multi-trait design used in this study helps identify genetic signals that may be diluted in single-trait analyses, potentially improving detection of loci with pleiotropic effects across liver disease phenotypes. However, multi-trait study designs also introduce interpretive complexity, since shared signals may reflect genetic overlap with related conditions — such as fatty liver disease, obesity-related metabolic dysfunction, or alcohol metabolism — rather than cirrhosis specifically.

Genes including PNPLA3, TM6SF2, and SERPINA1 have appeared in multiple independent studies of liver disease phenotypes, lending additional credibility to these associations. The confidence rating for this trait is moderate, reflecting that while these genetic signals are biologically plausible and replicated across related phenotypes, their translation to individualized risk estimates remains uncertain. Research suggests these variants are best understood as potential modifiers of population-level risk patterns, not as standalone predictors.

KEY STAT ClinVar records pathogenic variants in SERPINA1 linked to alpha-1-antitrypsin deficiency, a recognized monogenic cause of liver disease — underscoring that the same gene implicated in common-variant cirrhosis associations also harbors rare high-impact mutations (ClinVar, NCBI, accessed 2026-05-29).

How liver cirrhosis affects you

Liver cirrhosis develops silently in many cases, with symptoms emerging only after substantial scarring has accumulated. Early-stage fibrosis is often asymptomatic, and people may not know they have developing liver disease until a blood test, imaging study, or clinical evaluation reveals abnormalities. This silent progression is one reason that identifying underlying risk factors — whether genetic, behavioral, or clinical — carries practical significance.

As cirrhosis advances, complications can include portal hypertension, fluid accumulation in the abdomen (ascites), impaired coagulation, and elevated risk of liver cancer. Not everyone with genetic variants associated with cirrhosis risk develops the condition; the trait reflects probabilistic associations at the population level, shaped by lifestyle, other health conditions, medications, and environmental exposures.

Fat accumulation in the liver (hepatic steatosis) is a key intermediate phenotype connecting several of these genetic signals to liver injury. Genes like PNPLA3 and TM6SF2 appear to influence hepatic lipid handling, which in turn may affect susceptibility to inflammation and fibrosis under conditions of metabolic stress or alcohol exposure. Understanding this pathway is one reason liver genetics research has converged on metabolic risk as a key area of study.

For people with a family history of liver disease or known risk factors such as chronic alcohol use, obesity, or hepatitis infection, understanding the genetic landscape of liver-related traits may offer useful context for conversations with clinicians about monitoring and preventive strategies.

Working with your liver cirrhosis profile

Genetic information about liver cirrhosis risk is most useful when interpreted alongside clinical context. For people who have no known liver disease, a genetic signal suggesting elevated population-level risk may prompt earlier discussions with a clinician about baseline liver function testing, particularly if other risk factors are present.

Several modifiable factors are consistently linked to liver health in the scientific literature. Alcohol consumption is among the most potent environmental modifiers of liver fibrosis risk; research suggests that genetic variants like PNPLA3 and TM6SF2 may interact with alcohol exposure, amplifying liver injury in those with certain genotypes. This does not mean people with these variants will develop cirrhosis from moderate alcohol use, but it is a context in which the genetic information may be clinically relevant.

Maintaining a healthy body weight and avoiding obesity-related metabolic dysfunction reduces hepatic fat burden, which is relevant to the biological pathways associated with PNPLA3 and TM6SF2. Management of viral hepatitis infections — hepatitis B and C — through available treatments has transformed outcomes for many people with liver disease, and genetic risk profiles do not alter the importance of testing and treating these infections.

For individuals with a known SERPINA1 variant associated with alpha-1-antitrypsin deficiency, specialist evaluation is appropriate regardless of the common-variant signals discussed here; that condition represents a distinct clinical entity.

Genetic information in this area is one data point among many. Clinicians use liver enzyme panels, imaging, and clinical history alongside any genetic context to assess liver health meaningfully.

Liver cirrhosis risk sits at the intersection of several biological themes that recur across the ExomeDNA trait catalog. The genes involved here — particularly PNPLA3, TM6SF2, and HSD17B13 — appear in multiple liver-adjacent phenotypes, making this trait a useful anchor for understanding a broader genetic landscape.

Metabolic and liver-related traits closely connected to this one include non-alcoholic fatty liver disease associations (where PNPLA3 and TM6SF2 are also prominent), liver enzyme levels such as ALT and AST, and traits related to lipid metabolism and obesity. The SERPINA1 gene connects liver disease risk to lung-related phenotypes through its role in alpha-1-antitrypsin biology.

For further reading on related ExomeDNA traits, see:

Non-Alcoholic Fatty Liver Disease Risk
ALT Enzyme Levels
Metabolic Syndrome Risk
Type 2 Diabetes Risk — cross-category: Metabolism & Hormones
Body Mass Index Genetic Influence — cross-category: Physical Traits

For gene-level detail, see the PNPLA3 gene page, which covers this gene's role across liver and metabolic phenotypes in the ExomeDNA catalog.

Frequently asked questions

Does having these gene variants mean someone will develop cirrhosis? No. These genetic signals reflect population-level associations identified in large genome-wide studies. Carrying a variant near PNPLA3, TM6SF2, or another gene in this analysis indicates that people with that variant have, on average, somewhat different statistical patterns of liver disease risk compared to those without it — not that any individual will or will not develop cirrhosis. Liver disease is shaped by a complex interplay of genetics, alcohol use, metabolic health, infections, medications, and other factors. Genetic information in this context is best treated as one input to a broader clinical picture.

What lifestyle factors are most relevant to liver health for people with elevated genetic risk signals? Research consistently points to alcohol consumption, body weight, and metabolic health as the modifiable factors most clearly linked to liver fibrosis progression. For people who carry variants in genes like PNPLA3 or TM6SF2, some studies suggest that alcohol exposure may interact with these variants to increase liver injury risk compared to those without them. Managing weight, limiting alcohol, and treating hepatitis infections if present are the primary evidence-based areas of focus — though any personalized health plan should be developed with a qualified clinician.

What is the PNPLA3 gene, and why does it appear so often in liver disease research? PNPLA3 encodes a protein expressed in liver and fat cells that appears to play a role in how triglycerides are processed within liver tissue. Certain variants in this gene have been among the most consistently replicated findings in genome-wide studies of non-alcoholic fatty liver disease, alcoholic liver disease, and cirrhosis. Research suggests that specific PNPLA3 variants are associated with increased hepatic fat accumulation, which may prime the liver for inflammation and subsequent fibrosis. Its prominence in the literature reflects both its biological plausibility and its appearance across multiple independent study populations.

What does SERPINA1 have to do with liver disease? SERPINA1 encodes alpha-1-antitrypsin, a protein produced by the liver that normally circulates in the blood to inhibit tissue-damaging enzymes. Certain SERPINA1 variants — particularly those associated with alpha-1-antitrypsin deficiency — cause the protein to misfold and accumulate inside liver cells rather than being secreted properly. This accumulation can trigger liver cell stress and injury. Both rare high-impact mutations (associated with the clinical condition alpha-1-antitrypsin deficiency) and common variants near SERPINA1 appear in liver disease genetic studies. The signal in this trait primarily reflects common-variant associations, but the biology of the gene provides strong mechanistic context.

Should someone with elevated liver cirrhosis risk signals change their clinical monitoring? This is a question for a clinician to answer based on a full health history. In general, people who carry genetic variants associated with liver risk patterns, particularly when combined with other risk factors such as obesity, alcohol use, or a family history of liver disease, may benefit from baseline liver function testing and periodic monitoring. A clinician can determine whether imaging or specialist referral is appropriate given an individual's complete profile. Genetic information is one input; it neither replaces clinical evaluation nor makes routine clinical care unnecessary.

References

[1] Emdin et al. Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. Gastroenterology. 2021. PMID: 33310085.

Data sources:

GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
Open Targets Platform (CC0 1.0, accessed 2026-05-29)
ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

By the ExomeDNA Research Team

FDA wellness compliance statement: This content is intended for educational and informational purposes only. ExomeDNA's genetic reports are wellness products, not clinical tools, and are not substitutes for professional health guidance. Genetic variants discussed reflect population-level associations from published research. Individual genetic results should be interpreted with the guidance of a qualified healthcare provider.

Browse all traits →